Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kazuko Matsuoka
A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Journal of Ovarian Research
Gynecology
Oncology
Obstetrics
Related publications
Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The Lancet Oncology
Oncology
An Open-Label, Randomized, Phase II Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Bevacizumab in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Previously Treated With Bevacizumab for Front-Line or Platinum-Sensitive Ovarian Cancer: Rationale, Design, and Methods of the Japanese Gynecologic Oncology Group Study JGOG3023
BMC Cancer
Cancer Research
Oncology
Genetics
Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Pegylated Liposomal Doxorubicin for Platinum-Resistant or Refractory M�llerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube and Peritoneal Carcinoma): A Single-Institutional Experience
Oncology Letters
Cancer Research
Oncology
Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Phase II Trial of Lapatinib and Topotecan (LapTop) in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Salpingo-Oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation
JAMA - Journal of the American Medical Association
Medicine
